The impact of AirSeal® on complications and pain management during robotic-assisted radical prostatectomy: a single-tertiary center study

dc.contributor.authorAyoub, Christian Habib
dc.contributor.authorArmache, Alexandre Khalil
dc.contributor.authorEl-Asmar, Jose
dc.contributor.authorEl-Achkar, Adnan
dc.contributor.authorAbdulfattah, Suhaib
dc.contributor.authorBidikian, Nayda
dc.contributor.authorChawareb, Elia Abou
dc.contributor.authorHoyek, Elio
dc.contributor.authorEl Hajj, Albert Elias
dc.contributor.departmentSurgery
dc.contributor.departmentDivision of Urology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:14:24Z
dc.date.available2025-01-24T12:14:24Z
dc.date.issued2023
dc.description.abstractPurpose: We aimed to compare perioperative outcomes, post-operative complications, and opioid use between AirSeal® and non-AirSeal® robotic-assisted radical prostatectomy (RARP). Methods: We retrospectively collected data on 326 patients who underwent elective RARP at our institution either with or without AirSeal®. The first 60 cases were excluded accounting for the institutions’ learning curve of RARP. Patient demographics, oncologic, pathologic, and surgical characteristics between AirSeal® and non-AirSeal® cases were compared. Furthermore, outcomes of interest including operative time, length of stay, morbidity, and opioid use for pain management were compared between the two groups. Univariate linear and logistic regression models were developed. Results: The AirSeal® group consisted of 125 (38.3%) patients while the non-AirSeal® group consisted of 201 (61.7%) patients. No statistically significant difference was seen in terms of patient demographics, oncologic characteristics, surgical characteristics, and pathologic characteristics between the two groups. In addition, univariate linear regression showed that RARP with AirSeal® displayed shorter operative times by 12.3 min and a shorter length of hospital stay by 0.5 days compared to the non-AirSeal® group (p < 0.001). Furthermore, the AirSeal® group witnessed lower odds of Clavien-Dindo (CVD) Class > 2 complications (OR = 0.102) and a lower need for opioid use (OR = 0.49) compared to the non-AirSeal® group (p < 0.022). Conclusion: RARP using AirSeal® is associated with shorter operative times, shorter length of hospital stays, lower odds of CVD > 2 complications, and lower odds of opioid use with respect to non-AirSeal® RARP. The efficacy and cost effectiveness of using the AirSeal® system during RARP should be further studied and evaluated by clinical trials. © 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
dc.identifier.doihttps://doi.org/10.1007/s00345-023-04573-y
dc.identifier.eid2-s2.0-85171171992
dc.identifier.pmid37704868
dc.identifier.urihttp://hdl.handle.net/10938/33184
dc.language.isoen
dc.publisherSpringer Science and Business Media Deutschland GmbH
dc.relation.ispartofWorld Journal of Urology
dc.sourceScopus
dc.subjectLow pressure pneumoperitoneum
dc.subjectMorbidity
dc.subjectOutcomes
dc.subjectProstatectomy
dc.subjectRobotic surgical procedures
dc.subjectAnalgesics, opioid
dc.subjectCardiovascular diseases
dc.subjectHumans
dc.subjectMale
dc.subjectPain management
dc.subjectPostoperative complications
dc.subjectRetrospective studies
dc.subjectTreatment outcome
dc.subjectNarcotic analgesic agent
dc.subjectAnalgesia
dc.subjectCardiovascular disease
dc.subjectHuman
dc.subjectPostoperative complication
dc.subjectProcedures
dc.subjectRetrospective study
dc.subjectRobot assisted surgery
dc.titleThe impact of AirSeal® on complications and pain management during robotic-assisted radical prostatectomy: a single-tertiary center study
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2023-474.pdf
Size:
449.15 KB
Format:
Adobe Portable Document Format

Collections